TITLE

Dextromethorphan Hydrobromide and Quinidine Sulfate Tablets (Nuedexta)

AUTHOR(S)
Elliot, William T.; Chan, James
PUB. DATE
December 2010
SOURCE
Internal Medicine Alert;12/29/2010, Vol. 32 Issue 24, p190
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the drug dextromethorphan (DEX)/quinidine (QUIN), a treatment for pseudobulbar affect, by the U.S. Food and Drug Administration (FDA).
ACCESSION #
57803293

 

Related Articles

  • The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration. King, Rebecca R; Reiss, Jeffrey P // Degenerative Neurological & Neuromuscular Disease;Apr2013, Vol. 3, p23 

    Pseudobulbar affect is a disorder resulting from neurologic damage manifesting as sudden, stereotyped affective outbursts that are not reflective of internal emotion. A literature review was completed to examine the current understanding of the epidemiology, characterization, diagnosis,...

  • Dextromethorphan/Quinidine.  // CNS Drugs;2011, Vol. 25 Issue 5, p435 

    The article focuses on the clinical efficiency and tolerability of the drug Dextromethorphan/Quinidine in the treatment of pseudobulbar affect. As stated, pseudobulbar effect is characterized by uncontrollable laughing or crying that unrelated to the emotions felt by the patient. It states that...

  • Treatment helps control involuntary outbursts?  // Hospice Management Advisor;May2010, Vol. 15 Issue 5, p55 

    The article presents the new treatment for pseudobulbar affect (PBA), a neurological condition of involuntary expression of patient. Erik P. Pioro, director of the Section for ALS and Related Disorder at the Ohio Clinic, says that the abnormalities can affect the patient and caregiver...

  • Zenvia Posts Positive Phase III Results in PBA.  // Bioworld Week;8/17/2009, Vol. 17 Issue 33, p3 

    The article reports on the positive Phase III results in pseudobulbar affect (PBA) with the drug Zenvia from biotech company Avanir Pharmaceuticals Inc. in Aliso Viejo, California. It states that the results in PBA combine the dextromethorphan synthetic morphine derivative in Zenvia with the...

  • Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers. Schoedel, Kerri A.; Pope, Laura E.; Sellers, Edward M. // Clinical Drug Investigation;2012, Vol. 32 Issue 3, p157 

    Background and Objective: The novel combination of dextromethorphan (DM) and quinidine (Q) [DMQ] has been extensively studied in well controlled clinical trials as treatment for pseudobulbar affect (PBA), and is the first US Food and Drug Administration (FDA)-approved treatment for this...

  • Dextromethorphan and Quinidine.  // AHFS Consumer Medication Information;Jul2019, p1 

    The combination of dextromethorphan and quinidine is used to treat pseudobulbar affect (PBA; a condition of sudden, frequent outbursts of crying or laughing that can not be controlled) in people with certain conditions such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease; condition...

  • No Relation between Physical Disability Scores and Severity of PBA in MS. Buckley, Rita // MD Conference Express;Apr2012, Vol. 12 Issue 2, p7 

    Pseudobulbar affect (PBA) is a neurological condition of disinhibition of emotional expression characterized by uncontrollable, exaggerated, and often inappropriate outbursts of laughter and/or crying that may cause severe distress, embarrassment, and social dysfunction. This article discusses...

  • Clinical Study on Jin's Needling Treatment of Apoplectic Pseudobulbar Palsy. Xiaojun Chen; Lifang Chen; Zhanglian Wang; Zhen Fang; Xia Li // International Journal of Clinical Acupuncture;Apr-Jun2015, Vol. 24 Issue 2, p77 

    Objective: To observe the clinical curative effect of Jin's needling treatment on apoplectic Pseudobulbar Palsy. Methods: 80 patients diagnosed with apoplectic pseudobulbar paralysis were randomly divided into a treatment group and a control group with 40 cases in each group. On the basis of...

  • An Effective Long-Term Treatment for Pseudobulbar Affect?  // Neurology Reviews;Jun2010, Vol. 18 Issue 6, p11 

    The article discusses the efficacy of dextromethorpan and quinidine as treatment for pseudobulbar affect, an episode of involuntary laughing and crying. With the combination of dextromethorpan and quinidine, it notes that it is safe, effective and well-tolerated treatment for pseudobulbar...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics